Share this article

Roche has received 510(k) clearance from US Food and Drug Administration (FDA) for its cobas MRSA / SA Test for early and simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) directly from nasal specimens.

The company claims the test can detect both organisms from a single specimen, offering accurate results to control MRSA / SA infections.

NorthShore University HealthSystem director of Microbiology and Infectious Diseases Research Lance Peterson said: "Numerous successful surveillance programmes have led to a significant decrease in the rate of MRSA clinical infection in many organisations, and a dramatic reduction in post-operative surgical infections when screening for SA is done.

"Importantly, the fight against healthcare-associated infections continues to advance, as evidenced by this new test that can rapidly detect both MRSA and SA in a single assay.

"The cobas MRSA / SA Test demonstrated excellent performance in detecting both MRSA and SA strains in samples collected throughout the US.

"The cobas MRSA / SA Test is a polymerase chain reaction (PCR) based assay, which runs on the automated cobas 4800 System."

"Compared to culture testing, the cobas MRSA / SA Test offers confidence in identifying colonised patients the first time they are evaluated, aiding in the prevention of MRSA disease and post-operative SA surgical infections."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The cobas MRSA / SA Test is a polymerase chain reaction (PCR) based assay, which runs on the automated cobas 4800 System.

It offers simplified workflow available, with a simple de-cap and loading of the primary sample vial on the cobas 4800 System.

Roche Molecular Diagnostics head Paul Brown said: "Healthcare-associated infections continue to be a leading cause of mortality in US medical settings.

"With the addition of the cobas MRSA / SA Test to our expanding menu of tests for the cobas 4800 System, Roche offers laboratories and clinicians a highly efficient molecular solution to aid in the overall management and prevention of healthcare-associated infections, leading to lower costs for hospitals and optimal patient care."

The cobas 4800 System is said to provide walkaway automation of nucleic acid purification, PCR setup and real-time PCR amplification and detection, which will allow laboratories to achieve maximum efficiency.

The expanding system menu currently available in the US includes cobas CT / NG Test (chlamydia / gonorrhoea), cobas HPV Test, cobas BRAF V600 Mutation Test and cobas EGFR Mutation Test.